SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001562180-20-005102
Filing Date
2020-07-13
Accepted
2020-07-13 08:28:56
Documents
1
Period of Report
2020-07-13

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 3  
1 PRIMARY DOCUMENT primarydocument.xml 3 3101
  Complete submission text file 0001562180-20-005102.txt   4507
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Issuer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address
Karydas Daphne (Reporting) CIK: 0001816952 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37708 | Film No.: 201024354